Regeneron: III:REGN1979: A PHASE 3, OPEN LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 × ANTI-CD3BISPECIFIC ANTIBODY, IN COMBINATION WITH CHOP (O-CHOP) VERSUS RITUXIMAB IN COMBINATION WITH CHOP (D